FDA's Francis R.W. Godwin (CDER) and Kathleen Jones, PhD (CBER) detail a record pace of drug warning letters and the CGMP deficiencies most commonly cited in biologics facility inspections.
|Articles|May 1, 2018
- BioPharm International-05-01-2018
- Volume 31
- Issue 5
BioPharm International, May 2018 Issue (PDF)
Click the title above to open the BioPharm International May 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 8 years ago
Harmonization of Batch Recordsover 8 years ago
Gottlieb Tackles Tough Issues in First Year at FDAover 8 years ago
Understanding Validation and Technical Transfer, Part 2over 8 years ago
Leveraging Data for Better Biopharmaceutical Process Controlover 8 years ago
Key Ingredients to Healthcare’s Futureover 8 years ago
NIST Spectroscopic Measurement Standardsover 8 years ago
Managing Uncertainty in Continuous Biomanufacturingover 8 years ago
Putting Viral Clearance Capabilities to the Testover 8 years ago
CDMOs Driving Emerging Bio/Pharma SuccessAdvertisement
Related to this article
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Inebilizumab (Uplizna) cut MG-ADL scores by 1.9 points versus placebo, supporting its approval in Japan for myasthenia gravis.
Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
Today’s biopharma news highlights GSK’s myeloma strategy, Insilico’s AI longevity research, and innovations that may improve future treatment outcomes.
As data volumes explode, clinical data harmonization, hybrid cloud, and AI are reshaping biopharma IT into the industry's core growth engine.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Advertisement
Advertisement